Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol

Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol

Abstract Background In case of locally advanced and/or non-metastatic unresectable esophageal cancer, definitive chemoradiotherapy (CRT) delivering 50 Gy in 25 daily fractions in combination with platinum-based regimen remains the standard of care resulting in a 2-year disease-free survival of 25% w...

Full description

Bibliographic Details
Main Authors: Anouchka Modesto, David Tougeron, Pierre Tremolières, Philippe Ronchin, Ariane Darut Jouve, Delphine Argo Leignel, Véronique Vendrely, Olivier Riou, Jérôme Martin-Babau, Samuel Le Sourd, Xavier Mirabel, Thomas Leroy, Florence Huguet, Lucile Montaigne, Isabelle Baumgaertner, Marion Deslandres, Elizabeth Moyal, Catherine Seva, Janick Selves, Philippe Otal, Veronica Pezzella, Rosine Guimbaud, Thomas Filleron, Laurent Quéro
Format: Article
Language:English
Published: BMC 2023-10-01
Series:BMC Cancer
Subjects:
Esophagus carcinoma
Randomized trial
Phase II
Chemo-radiotherapy
Immunotherapy
Anti-PD-L1
Online Access:https://doi.org/10.1186/s12885-023-11227-0

Internet

https://doi.org/10.1186/s12885-023-11227-0

Similar Items